Abstract 90P
Background
Neutrophils (Nph) can play both protumor (N2) and antitumor (N1) roles at different stages of carcinogenesis. The tumor microenvironment promotes Nph polarization and enhances pro-angiogenic properties, contributing to changes in serum endothelial growth factor-A (VEGF-A) levels (Amorim C. et al., 2022).The aim of the study was to evaluate the ability of circulating neutrophils to produce VEGF-A during the progression of kidney cancer (KC).
Methods
The object of the study was the blood Nph of patients with KC before treatment, clear cell type I stage (T1N0M0G1, n=28, 60 years), II stage (T2N0M0G2, n=15, 61 years) and III stage (T3N0M0G2, n=15, 63 years) and the control group (n=15, 54 years). RNA was isolated from the peripheral blood Nph fraction on SileksMagNA magnetic particles (Sileks, Russia). The reverse transcription reaction was carried out and the expression of the VEGF-A gene was determined by quantitative PCR using primers (Evrogen, Russia). The level of VEGF-A in serum (pg/ml) was determined by ELISA (Vector-Best-Volga, Russia). The results are presented as Me (Q1-Q3). Statistical processing was performed in Statistica 13 (Mann–Whitney U test, Spearman correlation coefficient (p<0.05)). The study was approved by the Ethics Committee of IME&PK UlSU (protocol No. 1 of 01/15/2020).
Results
We found an increase in the serum level of VEGF-A at all stages of KC (stage I: 227.34 (227.34-399.49), p=0.002; stage II: 337.52 (329.33-692.18), p = 0.0005; III stage: 372.99 (282.99-545.82), p=0.001) relative to the control group (136.34 (91.01-168.95)). This may be due to the development of the angiogenic process during the progression of KC. The absolute amount of Nph decreased depending on the stage of KC: 4.6x109/l at stage I, 3.95x109/l - at stage III, 3.75x109/l - at stage IV. Expression of the VEGF-A gene by circulating Nph did not change at different stages of KC. However, at stage III KC, a correlation was found between VEGF-A gene expression in Nph and the level of this factor in serum (r=0.321, p=0.05).
Conclusions
Our results suggest that circulating Nph in KC has a high potential for VEGF-A production. At the same time, in stage III of KC, the serum level of VEGF-A is associated with an increased release of intracellular VEGF-A from Nph.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract